Wall Street swoons over Amgen's D-mab future

It's been a long time since I've heard the words "love" and "Amgen" in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's performance in a recent clinical trial. Oppenheimer's Bret Holley says the drug is on track to break the billion-dollar mark in 2010 with an approval possible in 2009. And that helped send shares of Amgen surging to a 14-month high.

- reaad the story from the Los Angeles Times

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.